Introduction
Chronic heart failure (CHF) is a complex clinical syndrome and a leading cause of global mortality. A central mechanism in CHF progression is the apoptosis of myocardial and endothelial cells, often initiated by a cascade of inflammatory cytokines. While B-type natriuretic peptide (BNP) is a standard diagnostic tool, its efficacy is limited in early-stage patients (NYHA Class I-II), where symptoms are often mild or absent. Recent research has highlighted the importance of "dark matter" in the genome—long non-coding RNAs (lncRNAs) and microRNAs (miRNAs)—in regulating cardiovascular health. This study explores the role of the lnc-NOS2P3-miR-939-5p axis in modulating inflammation-induced cell death in CHF.
Methods
The study utilized a cohort of 111 participants, including 75 CHF patients and 36 healthy controls from Shanghai East Hospital. Patients were categorized by NYHA functional classification. Bioinformatics tools, including TargetScan and DIANA-lncBase, were used to predict interactions between lncRNAs, miRNAs, and target mRNAs.
Experimental validation was conducted using human umbilical vein endothelial cells (HUVECs) and rat H9C2 myocardial cells. Techniques included:
- Loss-and-Gain of Function: miR-939-5p mimics and antagomirs were used to modulate miRNA levels.
- Luciferase Reporter Assays: To confirm direct binding between miR-939-5p and the 3’UTR of target genes (iNOS and TNFα).
- Quantification: RT-qPCR and Western Blotting measured RNA and protein expression, while flow cytometry quantified cell apoptosis rates.
Results
miR-939-5p as a Potential Early Biomarker
Serum levels of miR-939-5p were significantly higher in CHF patients than in controls. Notably, the increase was more pronounced in early-stage patients (NYHA I-II) compared to those in advanced stages (NYHA III-IV). In the early stages, miR-939-5p levels did not correlate with BNP, suggesting it could serve as an independent diagnostic marker where BNP might be less sensitive. In contrast, miR-939-5p was positively correlated with BNP in NYHA III-IV patients, indicating its relevance across the disease spectrum.
The Protective Role of miR-939-5p
Functional assays demonstrated that miR-939-5p acts as a protective "brake" on inflammation. Increasing miR-939-5p levels via mimics dose-dependently promoted cell proliferation and inhibited apoptosis in HUVECs and H9C2 cells treated with inflammatory cytokines. Luciferase assays confirmed that miR-939-5p directly targets and suppresses iNOS and TNFα, reducing TNFα activity by approximately 75%.
The lnc-NOS2P3 Molecular Sponge
The study identified lnc-NOS2P3 as a competitive endogenous RNA (ceRNA) that "sponges" miR-939-5p. By binding to the miRNA, lnc-NOS2P3 prevents it from inhibiting iNOS and TNFα. Knocking down lnc-NOS2P3 effectively released miR-939-5p, thereby reducing inflammatory cytokine-induced apoptosis and restoring cellular vitality.
Discussion
The discovery of the lnc-NOS2P3/miR-939-5p/iNOS-TNFα axis provides a new mechanistic understanding of CHF pathogenesis. The paradoxical elevation of miR-939-5p in early-stage CHF suggests a compensatory response by the body to mitigate initial myocardial damage.
However, several limitations remain. The study's mechanistic findings are based on in vitro cell cultures, and the lack of homologous sequences for this specific axis in common lab animals (mice/rats) complicates in vivo validation. Furthermore, while miR-939-5p shows therapeutic promise, developing targeted delivery systems for heart tissue remains a significant hurdle. Larger-scale, multi-center trials are necessary to confirm the clinical utility of miR-939-5p as a biomarker.
Conclusion
The lnc-NOS2P3-miR-939-5p axis plays a vital role in regulating cell survival during CHF. miR-939-5p represents a promising biomarker for early diagnosis and a potential target for future RNA-based therapies aimed at reducing inflammation-induced heart damage.
Summary updated